BioSpace News Archive

MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced that the Company will release its financial results for the first quarter ended March 31, 2023 on Tuesday, May 30, 2023.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, provided a business update, following the filing of its first quarter financial results on May 11.

Freeline Therapeutics Holdings plc announced that the company’s previously disclosed change to its American Depositary Share to ordinary share ratio has been made effective prior to the open of business on May 12, 2023.

BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.

Evox Therapeutics Ltd, a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles Annual Meeting, May 17-21, 2023, in Seattle.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries reported financial results for the first quarter ended March 31, 2023.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate progress.

Vyant Bio, Inc. is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [18F]FAPI-74 in its US Clinical Trial of flourine-18 labeled Fibroblast Activation Protein Inhibitor (FAPI).